Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jaguar HealthJAGX +1.14%21 Return-on-Tangible-Asset is 160.22% as of Mar. 2026. GuruFocus rates JAGX with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 1,415 Biotechnology companies, Jaguar Health ranks worse than 83.18% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Jaguar Health's annualizedNet Income for the quarter that ended in Mar. 2026 was $35.40 Mil. Jaguar Health's average total tangible assets for the quarter that ended in Mar. 2026 was $22.09 Mil. Therefore, Jaguar Health's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 160.22%.
The historical rank and industry rank for Jaguar Health's Return-on-Tangible-Asset or its related term are showing as below:
JAGX'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -511.86 Med: -200.42 Max: -117.37
Current: -121.39
During the past 13 years, Jaguar Health's highest Return-on-Tangible-Asset was -117.37%. The lowest was -511.86%. And the median was -200.42%.
JAGX's Return-on-Tangible-Asset is ranked worse than 83.18% of 1415
companies
in the Biotechnology industry
Industry Median: -35.49
vs JAGX: -121.39
Jaguar Health (NAS:JAGX) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Jaguar Health Return-on-Tangible-Asset Related Terms
Jaguar Health Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Jaguar Health's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JAGX vs TCRT, LABT, CPMV: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Jaguar Health's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jaguar Health Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jaguar Health's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Jaguar Health's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 160.22% mean?
Jaguar Health (JAGX) has a Return-on-Tangible-Asset of 160.22% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Jaguar Health and its competitors. According to the industry distribution chart, Jaguar Health ranks #1177 out of 1415 companies in the Biotechnology industry, placing it in the top 83.2%.
Is Jaguar Health's Return-on-Tangible-Asset too high?
Jaguar Health's current Return-on-Tangible-Asset is 160.22%. Based on the distribution chart, Jaguar Health ranks #1177 out of 1415 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Jaguar Health has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Jaguar Health's Return-on-Tangible-Asset compare to TCRT and LABT?
According to the Biotechnology industry distribution chart, Jaguar Health ranks #1177 out of 1415 companies for Return-on-Tangible-Asset. This places Jaguar Health in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Jaguar Health and its competitors. Jaguar Health's current Return-on-Tangible-Asset is 160.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jaguar Health stock overvalued right now?
Jaguar Health (JAGX) has a current Return-on-Tangible-Asset of 160.22%. The current Return-on-Tangible-Asset is 160.22%. Jaguar Health's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Jaguar Health (JAGX), the current Return-on-Tangible-Asset is 160.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
21GF Score
Get the complete analysis for JAGX
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JAGX has been successfully added to your 
